No-reflow phenomenon: Pathophysiology, diagnosis, prevention, and treatment. a review of the current literature and future perspectives

Angiology

Volumn 65, Issue 3, 2014, Pages 180-189

  Galasso, Gennaro ^a   Schiekofer, Stephan ^b   D'Anna, Carolina ^a   Gioia, Giuseppe Di ^a   Piccolo, Raffaele ^a   Niglio, Tullio ^a   Rosa, Roberta De ^a   Strisciuglio, Teresa ^a   Cirillo, Plinio ^a   Piscione, Federico ^c   Trimarco, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

diagnosis; future perspectives; ischemia reperfusion injury; microvascular obstruction; no reflow; pathophysiology; prevention; ST segment elevation myocardial infarction; treatment

Indexed keywords

ABCIXIMAB; ADENOSINE; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; NITROPRUSSIDE SODIUM; VERAPAMIL;

AUTOREGULATION; CARDIOVASCULAR MORTALITY; CONTRAST ECHOCARDIOGRAPHY; EDEMA; EMBOLIC PROTECTION DEVICE; ENDOTHELIAL DYSFUNCTION; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE REPERFUSION; HUMAN; LEUKOCYTE ADHERENCE; MICROVASCULAR ISCHEMIA; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RHEOLYTIC THROMBECTOMY; ST SEGMENT; THROMBECTOMY DEVICE; THROMBUS;

DIAGNOSIS; FUTURE PERSPECTIVES; ISCHEMIA-REPERFUSION INJURY; MICROVASCULAR OBSTRUCTION; NO-REFLOW; PATHOPHYSIOLOGY; PREVENTION; ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT;

CORONARY CIRCULATION; CORONARY VESSELS; HUMANS; INTRAOPERATIVE COMPLICATIONS; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84893571250     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712474336     Document Type: Review

References (82)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003 ; 361 (9351). 13-20
2. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008 ; 72 (7). 950-957
3. Butler MJ, Chan W, Taylor AJ, Dart AM, Duffy SJ. Management of the no-reflow phenomenon. Pharmacol Ther. 2011 ; 132 (1). 72-85
4. Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N Engl J Med. 2007 ; 357 (16). 1631-1638
5. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009 ; 54 (4). 281-292
6. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Neumann FJ, Chiariello M. Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials. Am Heart J. 2007 ; 153 (3). 343-353
7. Lee MS, Park SJ, Kandzari DE, et al. Saphenous vein graft intervention. JACC Cardiovasc Interv. 2011 ; 4 (8). 831-843
8. Sdringola S, Assali AR, Ghani M, et al. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc Interv. 2001 ; 54 (3). 318-324
9. Gregorini L, Marco J, Palombo C, et al. Postischemic left ventricular dysfunction is abolished by alpha-adrenergic blocking agents. J Am Coll Cardiol. 1998 ; 31 (5). 992-1001
10. Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood. 2002 ; 99 (8). 2794-2800
11. Reffelmann T, Kloner RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart. 2002 ; 87 (2). 162-168
12. Galiuto L. Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification. Heart. 2004 ; 90 (2). 123-125
13. Nallamothu B, Fox KA, Kennelly BM, et al. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The global registry of acute coronary events. Heart. 2007 ; 93 (12). 1552-1555
14. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999 ; 401 (6750). 282-286
15. Collet JP, Montalescot G.. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes. Diab Vasc Dis Res. 2005 ; 2(3): 136-143
16. Golino P, Maroko PR, Carew TE. The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation. 1987 ; 75 (1). 292-298
17. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996 ; 93 (2). 223-228
18. Niccoli G, Kharbanda RK, Crea F, Banning AP. No-reflow: again prevention is better than treatment. Eur Heart J. 2010 ; 31 (20). 2449-2455
19. Galiuto L, Garramone B, Scara A, et al. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. J Am Coll Cardiol. 2008 ; 51 (5). 552-559
20. Klug G, Mayr A, Schenk S, et al. Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012 ; 14(1): 46
21. Wu KC, Kim RJ, Bluemke DA, et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol. 1998 ; 32 (6). 1756-1764
22. Komamura K, Kitakaze M, Nishida K, et al. Progressive decreases in coronary vein flow during reperfusion in acute myocardial infarction: clinical documentation of the no reflow phenomenon after successful thrombolysis. J Am Coll Cardiol. 1994 ; 24 (2). 370-377
23. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning?. Circulation. 1995 ; 91 (1). 37-45
24. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000 ; 36 (4). 1202-1209
25. Capozzolo C, Piscione F, De Luca G, et al. Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results. Catheter Cardiovasc Interv. 2001 ; 53 (4). 464-473
26. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation. 2005 ; 112 (14). 2143-2148
27. Carter LI, Golzar JA, Cavendish JJ, Dixon SR. Embolic protection of saphenous vein graft percutaneous interventions. J Interv Cardiol. 2007 ; 20 (5). 351-358
28. Porto I, Choudhury RP, Pillay P, et al. Filter no reflow during percutaneous coronary interventions using the Filterwire distal protection device. Int J Cardiol. 2006 ; 109 (1). 53-58
29. Yip HK, Chen MC, Chang HW, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002 ; 122 (4). 1322-1332
30. Mizote I, Ueda Y, Ohtani T, et al. Distal protection improved reperfusion and reduced left ventricular dysfunction in patients with acute myocardial infarction who had angioscopically defined ruptured plaque. Circulation. 2005 ; 112 (7). 1001-1007
31. Limbruno U, De Caterina R. EMERALD. AIMI, and PROMISE: is there still a potential for embolic protection in primary PCI?. Eur Heart J. 2006 ; 27 (10). 1139-1145
32. De Rosa S, Cirillo P, De Luca G, et al. Rheolytic thrombectomy during percutaneous coronary intervention improves long-term outcome in high-risk patients with acute myocardial infarction. J Interv Cardiol. 2007 ; 20(4): 292-298
33. Antoniucci D, Valenti R, Migliorini A, et al. Comparison of rheolytic thrombectomy before direct infarct artery stenting versus direct stenting alone in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2004 ; 93 (8). 1033-1035
34. Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. J Am Coll Cardiol. 2010 ; 56 (12). 1298-1306
35. Ali A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol. 2006 ; 48 (2). 244-252
36. Chao CL, Hung CS, Lin YH, et al. Time-dependent benefit of initial thrombosuction on myocardial reperfusion in primary percutaneous coronary intervention. Int J Clin Pract. 2008 ; 62 (4). 555-561
37. Chevalier B, Gilard M, Lang I, et al. Systematic primary aspiration in acute myocardial percutaneous intervention: a multicentre randomised controlled trial of the export aspiration catheter. EuroIntervention. 2008 ; 4 (2). 222-228
38. Liistro F, Grotti S, Angioli P, et al. Impact of thrombus aspiration on myocardial tissue reperfusion and left ventricular functional recovery and remodeling after primary angioplasty. Circ Cardiovasc Interv. 2009 ; 2 (5). 376-383
39. Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009 ; 53 (4). 309-315
40. Lipiecki J, Monzy S, Durel N, et al. Effect of thrombus aspiration on infarct size and left ventricular function in high-risk patients with acute myocardial infarction treated by percutaneous coronary intervention. Results of a prospective controlled pilot study. Am Heart J. 2009 ; 157 (3). 583 e1-583 e7
41. Noel B, Morice MC, Lefevre T, et al. Thromboaspiration in acute ST elevation MI improves myocardial reperfusion. Circulation. 2005 ; 112 (Suppl 2). 519
42. Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008 ; 371 (9628). 1915-1920
43. Costopoulos C, Gorog DA, Di Mario C, Kukreja N Int J Cardiol. 2011 :
44. De Luca G, Navarese EP, Suryapranata H Int J Cardiol. 2012 :
45. Grube E, Hauptmann KE, Muller R, Uriel N, Kaluski E. Coronary stenting with MGuard: extended follow-up of first human trial. Cardiovasc Revasc Med. 2011 ; 12 (3). 138-146
46. Kaluski E, Groothuis A, Klapholz M, Seifart P, Edelman E. Coronary stenting with M-Guard: feasibility and safety porcine trial. J Invasive Cardiol. 2007 ; 19 (8). 326-330
47. Kaluski E, Tsai S, Klapholz M. Coronary stenting with MGuard: from conception to human trials. Cardiovasc Revasc Med. 2008 ; 9 (2). 88-94
48. Piscione F, Danzi GB, Cassese S, et al. Multicentre experience with MGuard net protective stent in ST-elevation myocardial infarction: safety, feasibility, and impact on myocardial reperfusion. Catheter Cardiovasc Interv. 2010 ; 75 (5). 715-721
49. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010 ; 31 (20). 2501-2555
50. Stone GW, Abizaid A, Silber S, et al. Prospective, randomized, multicenter evaluation of a polyethylene terephthalate micronet mesh-covered stent (MGuard) in ST-segment elevation myocardial infarction: the master trial[published online September 28, 2012]. J Am Coll Cardiol. 2012 ;:
51. Cassese S, Esposito G, Mauro C, et al. MGUard versus bAre-metal stents plus manual thRombectomy in ST-elevation myocarDial infarction pAtieNts-(GUARDIAN) trial: study design and rationale. Catheter Cardiovasc Interv. 2012 ; 79: 1118-11126
52. Piscione F, Piccolo R, Cassese S, et al. Is direct stenting superior to stenting with predilation in patients treated with percutaneous coronary intervention? Results from a meta-analysis of 24 randomised controlled trials. Heart. 2010 ; 96 (8). 588-594
53. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation. 1990 ; 82 (6). 2044-2051
54. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003 ; 285 (2). H579 - H588
55. De Luca G, Suryapranata H, Piscione F, Barbato E, Chiariello M. Stenting and abciximab in primary angioplasty: a review of current status. Ital Heart J. 2005 ; 6 (11). 874-880
56. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J. 2007 ; 28 (4). 443-449
57. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005 ; 293 (14). 1759-1765
58. De Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis. 2012 ; 222 (2). 426-433
59. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008 ; 118 (1). 49-57
60. Marzilli M, Gliozheni E, Marraccini P, Fedele S. Primary coronary angioplasty in acute myocardial infarction: clinical correlates of the 'no reflow' phenomenon. Int J Cardiol. 1998 ; 65 (suppl 1). S23 - S28
61. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the acute myocardial infarction study of adenosine (AMISTAD) trial. J Am Coll Cardiol. 1999 ; 34 (6). 1711-1720
62. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005 ; 45 (11). 1775-1780
63. Sdringola S, Assali A, Ghani M, et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv. 2000 ; 51(4): 394-399
64. Navarese EP, Buffon A, Andreotti F, et al. Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. Atherosclerosis. 2012 ; 222 (1). 1-7
65. Jaraki O, Strauss WE, Francis S, Loscalzo J, Stamler JS. Antiplatelet effects of a novel antianginal agent, nicorandil. J Cardiovasc Pharmacol. 1994 ; 23 (1). 24-30
66. Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003 ; 145 (1). 42-46
67. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J. 2006 ; 152 (5). 887 e9-887 e14
68. Mizumura T, Nithipatikom K, Gross GJ. Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog. Cardiovasc Res. 1995 ; 29 (4). 482-489
69. Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005 ; 112 (9). 1284-1288
70. Ikeda N, Yasu T, Kubo N, et al. Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction. Heart. 2004 ; 90 (2). 181-185
71. Ono H, Osanai T, Ishizaka H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J. 2004 ; 148 (4). E15
72. Ishihara M, Sato H, Tateishi H, et al. Effects of various doses of intracoronary verapamil on coronary resistance vessels in humans. Jpn Circ J. 1997 ; 61 (9). 755-761
73. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol. 1995 ; 75 (12). 778-782
74. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation. 1994 ; 89 (6). 2514-2518
75. Sezer M, Okcular I, Goren T, et al. Association of haematological indices with the degree of microvascular injury in patients with acute anterior wall myocardial infarction treated with primary percutaneous coronary intervention. Heart. 2007 ; 93 (3). 313-318
76. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008 ; 359 (5). 473-481
77. Byrne JG, Appleyard RF, Sun SC, et al. Cardiac-derived thromboxane A2. An initiating mediator of reperfusion injury?. J Thorac Cardiovasc Surg. 1993 ; 105 (4). 689-693
78. Galiuto L, DeMaria AN, del Balzo U, et al. Ischemia-reperfusion injury at the microvascular level: treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography. Circulation. 2000 ; 102 (25). 3111-3116
79. Zhao JL, Yang YJ, Cui CJ, You SJ, Gao RL. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br J Pharmacol. 2006 ; 149 (3). 243-249
80. Iwakura K, Ito H, Kawano S, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J. 2006 ; 27 (5). 534-539
81. Galaup A, Gomez E, Souktani R, et al. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation. 2012 ; 125 (1). 140-149
82. Zeng M, Yan H, Chen Y, et al. Suppression of NF-kappaB reduces myocardial no-reflow. PLoS One. 2012 ; 7 (10). e47306